“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

Novo Nordisk said on Wednesday it would begin selling ... as it grapples with shifts to the competitive dynamic of the US obesity drug market. The move comes just over a week after rival Eli ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

March 5, 2025 Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $ ...

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Novo Nordisk announced that the US Food and Drug Administration (FDA) has determined the shortage of Wegovy and Ozempic is resolved. The FDA's assessment confirms the US supply of these ...